Status:
COMPLETED
Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Disorder
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Attention-Deficit/Hyperactive Disorder (ADHD) in adults is associated with global impairments and deficits in quality of life. The ADHD functional impairments during adulthood usually persist even aft...
Eligibility Criteria
Inclusion
- Patients with ADHD
- Medicated with following drugs and minimum daily dosages:
- Methylphenidate ≥ 0.5 mg/kg Lisdexamfetamine ≥ 30mg Bupropion ≥ 150 mg Modafinil ≥ 200mg Imipramine ≥ 1mg/kg
- At least one month of stabilized dosage for any psychiatric medication.
- ADHD-Self Report Scale ≥ 20.
- Knowledge of oral and written communication in Portuguese
- IQ\>85 (intelligence quotient)
Exclusion
- diagnoses of Borderline or Anti-social personality disorders.
- diagnoses of autism spectrum disorder
- current episode of major depression or suicide toughs
- current episodes of mania or hypomania
- recent episodes of drug abuse (last 6 months)
- diagnoses of drug dependence
- patients that change their medications or their psychiatric conditions in the exclusion criteria above after the beginning of the protocol will have their data censored, but included in the intention to treat analyses. These patients will keep the right to attend all the sessions in the protocol at their discretion.
Key Trial Info
Start Date :
April 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 27 2019
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT03326427
Start Date
April 7 2018
End Date
March 27 2019
Last Update
February 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Pesquisa Clínica
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903